185 related articles for article (PubMed ID: 33414055)
1. Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.
Sakane T; Sakamoto Y; Masaki A; Murase T; Okuda K; Nakanishi R; Inagaki H
Clin Lung Cancer; 2021 Mar; 22(2):92-99.e4. PubMed ID: 33414055
[TBL] [Abstract][Full Text] [Related]
2. Genetic profiling of thymic carcinoma using targeted next-generation sequencing.
Shitara M; Okuda K; Suzuki A; Tatematsu T; Hikosaka Y; Moriyama S; Sasaki H; Fujii Y; Yano M
Lung Cancer; 2014 Nov; 86(2):174-9. PubMed ID: 25249426
[TBL] [Abstract][Full Text] [Related]
3. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
[TBL] [Abstract][Full Text] [Related]
4. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
5. Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.
Wang S; Gu Z; Zhu L; Han Y; Yu H; Fang W; Han B
Chin Med J (Engl); 2023 Nov; 136(22):2712-2721. PubMed ID: 37749819
[TBL] [Abstract][Full Text] [Related]
6. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis.
Moreira AL; Won HH; McMillan R; Huang J; Riely GJ; Ladanyi M; Berger MF
J Thorac Oncol; 2015 Feb; 10(2):373-80. PubMed ID: 25299233
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
8. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
9. Effect of clinicopathologic features on survival of patients with thymic carcinomas and thymic neuroendocrine tumors: A population-based analysis.
Song Q; Zhang LL; Qi Y; Xing KL; Wu XH
Curr Probl Cancer; 2019 Oct; 43(5):411-420. PubMed ID: 30952367
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
11. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of tumour size in completely resected thymic epithelial tumours.
Fukui T; Fukumoto K; Okasaka T; Kawaguchi K; Nakamura S; Hakiri S; Ozeki N; Hirakawa A; Tateyama H; Yokoi K
Eur J Cardiothorac Surg; 2016 Dec; 50(6):1068-1074. PubMed ID: 27999073
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma.
Kishibuchi R; Kondo K; Soejima S; Tsuboi M; Kajiura K; Kawakami Y; Kawakita N; Sawada T; Toba H; Yoshida M; Takizawa H; Tangoku A
Int J Oncol; 2020 Jan; 56(1):315-326. PubMed ID: 31746370
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database.
Fu H; Gu ZT; Fang WT; Fu JH; Shen Y; Han YT; Yu ZT; Li Y; Tan LJ; Pang LW; Chen KN
Ann Surg Oncol; 2016 Feb; 23(2):619-25. PubMed ID: 26474558
[TBL] [Abstract][Full Text] [Related]
15. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group.
Fukui T; Fukumoto K; Okasaka T; Kawaguchi K; Nakamura S; Hakiri S; Ozeki N; Hirakawa A; Tateyama H; Yokoi K
Eur J Cardiothorac Surg; 2016 Feb; 49(2):574-9. PubMed ID: 26547095
[TBL] [Abstract][Full Text] [Related]
17. Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma.
Karube Y; Kobayashi S; Maeda S; Sado T; Ishihama H; Chida M
J Cardiothorac Surg; 2016 May; 11(1):85. PubMed ID: 27387303
[TBL] [Abstract][Full Text] [Related]
18. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.
Tahara I; Oishi N; Mochizuki K; Oyama T; Miyata K; Miyauchi A; Hirokawa M; Katoh R; Kondo T
Endocr Pathol; 2020 Sep; 31(3):274-282. PubMed ID: 32594366
[TBL] [Abstract][Full Text] [Related]
19. Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis.
Zeng H; Yang W; Xu B; Zou J; Su C; Zhong B; Zhu H; Chen Z
BMC Cancer; 2020 Sep; 20(1):928. PubMed ID: 32993581
[TBL] [Abstract][Full Text] [Related]
20. Loss of p16
Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
